NCT01753232View on ClinicalTrials.gov

Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter

CompletedOBSERVATIONAL
Enrollment

108

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

August 31, 2015

Conditions
Hypercholesterolemia, FamilialLIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIA
Interventions
DEVICE

DALI-adsorber

Recording of treatment data. No extra interventional treatment

DEVICE

MONET-Lipoprotein filter

Only treatment data recording. No extra interventional treatment

Trial Locations (11)

14482

Dialysezentrum Potsdam, Potsdam

18059

Apheresezentrum Rostock, Rostock

30625

Zentrum für Nieren und Hochdruckkrankheiten Standort Heidering, Hanover

37075

Nephrologisches Zentrum Goettingen, Göttingen

39108

Dialysezentrum Magdeburg-Stattfeld, Magdeburg

45127

Nephrologische Gemeinschaftspraxis Dialysezentrum/Lipidzentrum, Essen

51105

Gemeinschaftspraxis Gysan, Heinzler, May, Hossmann, Cologne

55218

Apheresezentrum Ingelheim, Ingelheim

68309

Nierenzentrum Mannheim, Mannheim

87439

Medizinisches Versorgungszentrum, Kempten (Allgäu)

93053

Universitätsklinikum Regensburg Institut für Klinische Chemie und Laboratoriumsmedizin, Regensburg

All Listed Sponsors
lead

Fresenius Medical Care Deutschland GmbH

INDUSTRY

NCT01753232 - Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter | Biotech Hunter | Biotech Hunter